Lakefront Biotherapeutics NV (LKFT) Ownership
LKFT ownership summary
as of October 18, 2026- Institutions
- 23.6% of shares outstanding
- Insiders
- 25.45% of shares outstanding
- Shares outstanding
- 65.5M
- Float
- 474.4M shares available to trade
- Short interest
- 8.28% 3.3M shares short
- Days to cover
- 10.63 short interest down 2.8% vs prior month
- Institutions 23.63%
- Insiders 25.45%
- Other investors 50.92%
LKFT top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | TANG CAPITAL MANAGEMENT LLC | 5.77% | 3.8M | $113.2M | — | June 30, 2026 |
| 2 | Madison Avenue Partners, LP | 5.25% | 3.4M | $103.1M | +982,628 (+39.9%) | June 30, 2026 |
| 3 | Prosight Management, LP | 3.11% | 2.0M | $61.1M | +493,344 (+31.8%) | June 30, 2026 |
| 4 | EcoR1 Capital, LLC | 2.54% | 1.7M | $49.8M | — | June 30, 2026 |
| 5 | Ameriprise Financial Inc | 1.94% | 1.3M | $38.0M | −152,425 (−10.7%) | June 30, 2026 |
| 6 | Renaissance Technologies Corp | 0.62% | 408K | $12.2M | +92,400 (+29.3%) | June 30, 2026 |
| 7 | BlackRock Inc | 0.52% | 338K | $10.1M | +26,046 (+8.3%) | June 30, 2026 |
| 8 | Point72 Asset Management, L.P. | 0.41% | 270K | $8.1M | −62,311 (−18.8%) | June 30, 2026 |
| 9 | D. E. Shaw & Co LP | 0.30% | 198K | $5.9M | −17,874 (−8.3%) | June 30, 2026 |
| 10 | Millennium Management LLC | 0.28% | 181K | $5.4M | +73,178 (+67.8%) | June 30, 2026 |
| 11 | UBS Group AG | 0.26% | 168K | $5.0M | −7,141 (−4.1%) | June 30, 2026 |
| 12 | Susquehanna International Group, LLP | 0.23% | 152K | $4.5M | +138,499 (+1,034.6%) | June 30, 2026 |
| 13 | Dafna Capital Management LLC | 0.20% | 130K | $3.9M | — | June 30, 2026 |
| 14 | Citadel Advisors Llc | 0.13% | 88K | $2.6M | −36,085 (−29.0%) | June 30, 2026 |
| 15 | Two Sigma Investments LLC | 0.12% | 82K | $2.4M | +55,889 (+216.1%) | June 30, 2026 |
| 16 | NORGES BANK | 0.12% | 77K | $2.3M | −13,121 (−14.6%) | June 30, 2026 |
| 17 | ALPS Advisors Inc | 0.10% | 66K | $2.0M | +11,862 (+22.1%) | June 30, 2026 |
| 18 | The Goldman Sachs Group Inc | 0.09% | 57K | $1.7M | +11,210 (+24.7%) | June 30, 2026 |
| 19 | American Century Companies Inc | 0.06% | 41K | $1.2M | +2,014 (+5.2%) | June 30, 2026 |
| 20 | Barometer Capital Management Inc | 0.06% | 41K | $1.2M | +2,700 (+7.1%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 11 holders added 1.9M shares and 6 cut 289K.
LKFT top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Columbia Overseas Value Inst | 0.91% | 596K | $17.8M | −136,525 (−18.6%) | August 31, 2026 |
| 2 | HBM Healthcare Investments AG Ord | 0.58% | 378K | $11.3M | +378,326 (0.0%) | June 30, 2026 |
| 3 | iShares Biotechnology ETF | 0.52% | 339K | $10.1M | −2,568 (−0.8%) | September 30, 2026 |
| 4 | Columbia VP Overseas Core 3 | 0.43% | 280K | $8.4M | −66,232 (−19.1%) | June 30, 2026 |
| 5 | ALPS Medical Breakthroughs ETF | 0.13% | 88K | $2.6M | — | September 30, 2026 |
| 6 | Barometer International Equity A | 0.06% | 41K | $1.2M | — | September 30, 2026 |
| 7 | Steward Values Enhanced International I | 0.05% | 31K | $916,614 | +14,087 (+85.0%) | August 31, 2026 |
| 8 | Avantis International Equity ETF | 0.05% | 30K | $910,425 | — | September 30, 2026 |
| 9 | VALIC Company I International Value | 0.03% | 22K | $672,690 | −4,819 (−17.6%) | August 31, 2026 |
| 10 | Schwab International Opportunities | 0.02% | 16K | $471,045 | −9,578 (−37.8%) | June 30, 2026 |
| 11 | ActivePassive International Equity ETF | 0.02% | 15K | $452,865 | — | September 30, 2026 |
| 12 | ERSTE STOCK BIOTEC EUR R01 A | 0.02% | 14K | $418,600 | — | August 31, 2026 |
| 13 | iShares Nasdaq US Biotech ETF USD Acc | 0.02% | 12K | $359,667 | +100 (+0.8%) | September 30, 2026 |
| 14 | Avantis International Small Cp Eq ETF | 0.01% | 7,605 | $227,390 | — | September 30, 2026 |
| 15 | Invesco NASDAQ Future Gen 200 ETF | 0.01% | 4,208 | $125,819 | — | September 30, 2026 |
| 16 | Acadian Global Dev Enh EqC4i0.2000USDLU3 | 0.01% | 3,727 | $111,437 | — | June 30, 2026 |
| 17 | Prisma Cube | <0.01% | 3,000 | $89,700 | — | June 30, 2026 |
| 18 | Avantis® International Equity Instl | <0.01% | 2,478 | $74,092 | — | August 31, 2026 |
| 19 | VanEck Genomics and Healthcare Inn ETF | <0.01% | 2,462 | $73,614 | — | September 30, 2026 |
| 20 | China Universal NASDAQ Bio-Tch ETF(QDII) | <0.01% | 2,393 | $71,551 | +37 (+1.6%) | June 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
LKFT shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns LKFT
Institutional investors own 23.6% of Lakefront Biotherapeutics's shares and insiders 25.45%. The largest holder is TANG CAPITAL MANAGEMENT LLC with 5.77% of the shares (3.8M), as of June 30, 2026. Among the top 20 institutions, 11 added shares and 6 reduced their stake in the latest filings. Short interest is 8.28% of the float, or 10.63 days of average trading volume. The share count rose 119.7% since 2014.
Related: LKFT analyst forecast, LKFT key metrics. See the LKFT stock overview for the latest quote and news.
LKFT ownership FAQ
Who owns the most Lakefront Biotherapeutics stock?
The largest shareholders of Lakefront Biotherapeutics are TANG CAPITAL MANAGEMENT LLC (5.77%), Madison Avenue Partners, LP (5.25%), Prosight Management, LP (3.11%), EcoR1 Capital, LLC (2.54%), Ameriprise Financial Inc (1.94%).
What percentage of Lakefront Biotherapeutics is owned by institutions?
Institutions hold 23.6% of Lakefront Biotherapeutics's shares outstanding; insiders hold 25.45%.
Which funds own Lakefront Biotherapeutics?
The largest fund holders of Lakefront Biotherapeutics are Columbia Overseas Value Inst (0.91%), HBM Healthcare Investments AG Ord (0.58%), iShares Biotechnology ETF (0.52%), Columbia VP Overseas Core 3 (0.43%), ALPS Medical Breakthroughs ETF (0.13%).
What is Lakefront Biotherapeutics's short interest?
3.3M shares of Lakefront Biotherapeutics were sold short, 8.28% of the float; at the average daily volume it would take 10.63 days to cover.
How many shares of Lakefront Biotherapeutics are outstanding?
Lakefront Biotherapeutics has 65.5M shares outstanding, of which 474.4M are in the public float.